NSRX
Nasus Pharma LtdCompany with tickers: NSRX
CIK
2029039
CUSIP
M7071P109
Shares Outstanding
11,710,808
13F Activity (30d)
9 filings
7 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $1,235,000,000 | USD | 2025-12-31 | 20-F | 2026-03-25 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $4,904,000 | USD | 2025-12-31 | 20-F | 2026-03-25 |
| Research & Development | $2,237,000 | USD | 2025-12-31 | 20-F | 2026-03-25 |
| Operating Income | $-4,904,000 | USD | 2025-12-31 | 20-F | 2026-03-25 |
| Net Income | $-5,856,000 | USD | 2025-12-31 | 20-F | 2026-03-25 |
| EPS (Basic) | $-0.72 | USD/shares | 2025-12-31 | 20-F | 2026-03-25 |
| EPS (Diluted) | $-0.72 | USD/shares | 2025-12-31 | 20-F | 2026-03-25 |